[ad_1]
Professor Glenda Gray, executive director of the SA Medical Research Council and principal investigator for the J&J vaccine trial, was more cautious about launching AstraZeneca and has suggested waiting for the J&J vaccine, which is likely to be more beneficial.
She said: “I view vaccines in terms of individual and public benefit. In terms of AstraZeneca, I think we have to look at the data. ‘
Gray said an ongoing clinical trial on the AstraZeneca vaccine would be of great value. In this trial, 30,000 people were being tested and he was “fully enrolled.”
“The reason this is important is because it will give us information on serious illness and death, and people with comorbidities. One thing I would suggest is that … we evaluate the vaccine in the future, ”he said.
He said that during his state of the nation address on Thursday, President Cyril Ramaphosa was going to have to brief SA on the plans for the AstraZeneca vaccines, as the public needs to know the doses we have purchased.
Madhi, however, says that we should follow the directions of the World Health Organization which, after five hours of deliberation, concluded that there was still an important role for the AstraZeneca vaccine.
TimesLIVE
[ad_2]
